Evidence map›Paper›PMID 29423793›Full record

ReviewMethods in molecular biology (Clifton, N.J.)2018

What Can We Learn About Human Disease from the Nematode C. elegans?

Javier Apfeld, Scott Alper

Open access · greenAbstract readReview
In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 113 citations in OpenAlex.

  1. Application ofBiomolecules & therapeutics · 2026
    Review
  2. Toxicology research · 2026
    Article
  3. bioRxiv : the preprint server for biology · 2026
    Article
  4. The Effectiveness of Manuka Honey in TreatingmicroPublication biology · 2026
    Article
  5. Article
  6. Temporal Analysis of Embryonic Epidermal Morphogenesis inInternational journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. UtilizingJournal of developmental biology · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Javier ApfeldDepartment of Biology, Northeastern University, Boston, MA, 02115, USA.
Scott AlperDepartment of Biomedical Research, Center for Genes, Environment and Health, National Jewish Health, Denver, CO, 80206, USA. alpers@njhealth.org.
National Jewish Health · USNortheastern University · US

Funding

Toxin-induced alternative mRNA splicing in Toll-like receptor signaling pathwaysR01ES025161 · NIEHS · NATIONAL JEWISH HEALTH · PI ALPER, SCOTT · 2016 to 2020
$1.8M
NIEHS NIH HHS R01 ES025161
6 · The paper itself

Abstract

Numerous approaches have been taken in the hunt for human disease genes. The identification of such genes not only provides a great deal of information about the mechanism of disease development, but also provides potential avenues for better diagnosis and treatment. In this chapter, we review the use of the nonmammalian model organism C. elegans for the identification of human disease genes. Studies utilizing this relatively simple organism offer a good balance between the ability to recapitulate many aspects of human disease, while still offering an abundance of powerful cell biological, genetic, and genomic tools for disease gene discovery. C. elegans and other nonmammalian models have produced, and will continue to produce, key insights into human disease pathogenesis.

Indexed as

Disease Models, AnimalAnimalsCaenorhabditis elegansHumansCaenorhabditis elegansGenetic screensGenomic screensGFPRNAi

Identifiers

PMID29423793
PMCPMC6391162
OpenAlexW2792457053

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.